Eli Lilly Gives ~50 Covered Entities Five Days to Hand Over 340B Claims Data — or Lose Their Discounts

On June 1, Eli Lilly escalated its 340B claims-data fight, warning roughly 50 covered entities that they have five days to submit comprehensive claims data or stop receiving 340B price breaks — the first time the manufacturer has issued outright termination threats rather than reminder letters. The demand follows Lilly's policy announced in January and effective Feb. 1, 2026, which requires claims-level data for all 340B dispenses (including in-house pharmacies, not just contract pharmacies); STAT reports more than 2,300 entities have complied while up to 1,000 larger systems have refused. The first round targets hospital systems, but the policy applies to all covered entities — FQHCs that dispense Lilly products (insulin, oncology, psychiatric drugs) and have not enrolled in the data platform face the same termination risk. With North Dakota's contract-pharmacy law struck down and other state shields in litigation, this is the manufacturer-side pressure on 340B savings that FQHC pharmacy directors must act on now.